What is TG Therapeutics, Inc.'s Market Cap?

TG Therapeutics, Inc.'s Market Cap is $8.4B, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s Enterprise Value?

TG Therapeutics, Inc.'s Enterprise Value is $8.6B, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s Trailing P/E?

TG Therapeutics, Inc.'s Trailing P/E is 18.9×, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s Price / Sales?

TG Therapeutics, Inc.'s Price / Sales is 10.5×, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s EV / Revenue?

TG Therapeutics, Inc.'s EV / Revenue is 10.7×, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s EV / EBITDA?

TG Therapeutics, Inc.'s EV / EBITDA is 63.9×, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s Revenue (TTM)?

TG Therapeutics, Inc.'s Revenue (TTM) is $799.5M, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s Net Income (TTM)?

TG Therapeutics, Inc.'s Net Income (TTM) is $441.5M, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s EBITDA?

TG Therapeutics, Inc.'s EBITDA is $136.5M, based on as-reported figures from SEC (XBRL) filings.

What is TG Therapeutics, Inc.'s Diluted EPS (TTM)?

TG Therapeutics, Inc.'s Diluted EPS (TTM) is 2.88, based on as-reported figures from SEC (XBRL) filings.

TG Therapeutics, Inc. (TGTX) Financial Statements

TG Therapeutics, Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG001S8NH06

XNAS · usd

54.65▼ 1.09 (-1.96%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value

Trailing P/E

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close55.74

Day's Range54.24 – 57.14

52-Week Range26.76 – 59.30

Volume1.4M

Avg Volume2.1M

Share Statistics

Shares Outstanding

Employees399

ExchangeXNAS

Listed1995-12-14

Share count as of August 3, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about TG Therapeutics, Inc. (TGTX)

What is TG Therapeutics, Inc.'s Market Cap?: TG Therapeutics, Inc.'s Market Cap is $8.4B, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s Enterprise Value?: TG Therapeutics, Inc.'s Enterprise Value is $8.6B, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s Trailing P/E?: TG Therapeutics, Inc.'s Trailing P/E is 18.9×, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s Price / Sales?: TG Therapeutics, Inc.'s Price / Sales is 10.5×, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s EV / Revenue?: TG Therapeutics, Inc.'s EV / Revenue is 10.7×, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s EV / EBITDA?: TG Therapeutics, Inc.'s EV / EBITDA is 63.9×, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s Revenue (TTM)?: TG Therapeutics, Inc.'s Revenue (TTM) is $799.5M, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s Net Income (TTM)?: TG Therapeutics, Inc.'s Net Income (TTM) is $441.5M, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s EBITDA?: TG Therapeutics, Inc.'s EBITDA is $136.5M, based on as-reported figures from SEC (XBRL) filings.
What is TG Therapeutics, Inc.'s Diluted EPS (TTM)?: TG Therapeutics, Inc.'s Diluted EPS (TTM) is 2.88, based on as-reported figures from SEC (XBRL) filings.